Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
1. A method of immune therapy in a subject in need thereof which comprises the administration of a therapeutically effective amount of a human or humanized anti-CD154 antibody which is an IgG1 and the Fc region thereof comprises an E269R mutation and a K322A mutation and further comprises one additional Fc modification which consists of a P331G mutation or a V215A mutation.
2. The method of claim 1 , wherein the immune therapy further includes the administration of an antigen.
3. The method of claim 1 , wherein the treated subject has an allergic, autoimmune, or inflammatory condition.
4. The method of claim 1 , which suppresses humoral immunity.
5. The method of claim 1 , which suppresses T cell immunity.
6. The method of claim 1 , which is for treatment of an autoimmune condition selected from the group consisting of rheumatoid arthritis, Myasthenia gravis, systemic lupus erythematosus, Graves' disease, idiopathic thrombocytopenia purpura, hemolytic anemia, diabetes mellitus, psoriasis, inflammatory bowel disease, Addison's disease, Crohn's disease, uveitis, multiple sclerosis, lupus, and drug-induced autoimmune diseases.
7. The method of claim 1 , which is for treatment of a T cell-mediated autoimmune condition.
8. The method of claim 1 , which is for treatment or prevention of GVHD.
9. The method of claim 1 , wherein the treated subject is a transplant recipient.
10. The method of claim 9 , wherein the transplant recipient is a bone marrow transplant recipient.
11. The method of claim 1 , wherein the treated subject has cancer.
12. The method of claim 1 , wherein the treated subject has an allergic condition.
13. The method of claim 1 , wherein said anti-CD154 antibody comprises the V L complementarity determining regions (CDRs) of SEQ ID NO: 17, 18, and 19 and the V H CDRs of SEQ ID NO: 24, 25 and 26.
14. The method of claim 1 , wherein said anti-CD154 antibody comprises the V L polypeptide of said antibody has the amino acid sequence of SEQ ID NO: 13, 14, 15 or 16 and a V H polypeptide have the amino acid sequence of SEQ ID NO: 20, 21, 22 or 23.